News
Post hoc Analysis of the FRAME Study – Romosozumab in the Treatment of Osteoporosis in the European Population
An interesting finding from the FRAME study, which evaluated the treatment of postmenopausal women with osteoporosis using romosozumab, was the significant differences in fracture incidence among patients from various geographic regions. The following post hoc analysis specifically focused on data from European women.
Romosozumab vs. Teriparatide in Sequential Treatment of Osteoporosis in Women with a History of Fracture
The STRUCTURE study observed the effect of romosozumab and teriparatide on bone density in…
How Important is the Time Factor in the Treatment of Heart Failure?
Current guidelines emphasize the importance of early diagnosis and immediate treatment for patients…
Transthyretin Amyloidosis in Patients with Carpal Tunnel Syndrome
Carpal tunnel syndrome is considered a warning sign for cardiac amyloidosis. Amyloid deposits are…
Inhibition of Mutated KRAS Protein as a New Option for Targeted Treatment of Non-Small Cell Lung Cancer
RAS proteins are molecular switches for several intracellular signaling pathways. Their dysfunction…
MUDr. Tomáš Mašek: In the prevention of hemorrhoids, more use of venopharmaceuticals is needed
While in the past the diagnosis of hemorrhoids was inextricably linked to traditional surgical…
Balance and Rehabilitation – Firm on the Ground Even with Multiple Sclerosis
A large portion of patients with multiple sclerosis (MS) suffer from balance disorders. What are the...
Instead of NSAIDs, consider combining paracetamol with a weak opioid
Chronic non-cancer pain is a problem that primary care physicians encounter on a daily basis. In…
Fixed combination tramadol/paracetamol as an effective and safe option for long-term pain treatment even in polymorbid patients
Combined analgesics were historically recommended exclusively for the treatment of acute or…
Pharmacological Profile of Mavacamten and Key Studies of Its Use in HCM Treatment
A new addition to the treatment options for hypertrophic cardiomyopathy, approved for use in…